156 related articles for article (PubMed ID: 21641572)
1. A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology.
Killian JK; Bilke S; Davis S; Walker RL; Jaeger E; Killian MS; Waterfall JJ; Bibikova M; Fan JB; Smith WI; Meltzer PS
Am J Pathol; 2011 Jul; 179(1):55-65. PubMed ID: 21641572
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of PDL1 expression in breast cancer.
Sabatier R; Finetti P; Mamessier E; Adelaide J; Chaffanet M; Ali HR; Viens P; Caldas C; Birnbaum D; Bertucci F
Oncotarget; 2015 Mar; 6(7):5449-64. PubMed ID: 25669979
[TBL] [Abstract][Full Text] [Related]
3. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
4. High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer.
Salhab M; Patani N; Jiang W; Mokbel K
Breast Cancer; 2012 Apr; 19(2):153-60. PubMed ID: 20972741
[TBL] [Abstract][Full Text] [Related]
5. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
[TBL] [Abstract][Full Text] [Related]
7. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
9. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
10. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract][Full Text] [Related]
11. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
12. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.
Petrović N; Mandušić V; Stanojević B; Lukić S; Todorović L; Roganović J; Dimitrijević B
Med Oncol; 2014 Mar; 31(3):867. PubMed ID: 24488617
[TBL] [Abstract][Full Text] [Related]
13. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
[TBL] [Abstract][Full Text] [Related]
14. P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer.
Wazir U; Jiang WG; Yasaei H; Linne H; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2185-9. PubMed ID: 23645774
[TBL] [Abstract][Full Text] [Related]
15. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer.
Wazir U; Jiang WG; Sharma AK; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2179-83. PubMed ID: 23645773
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
17. STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession.
Xie J; Yang Y; Sun J; Jiao Z; Zhang H; Chen J
Clin Breast Cancer; 2019 Feb; 19(1):e195-e207. PubMed ID: 30253922
[TBL] [Abstract][Full Text] [Related]
18. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
19. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
[TBL] [Abstract][Full Text] [Related]
20. Can a phenotype for recessive inheritance in breast cancer be defined?
Ellberg C; Jönsson G; Olsson H
Fam Cancer; 2010 Dec; 9(4):525-30. PubMed ID: 20549370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
